ICAM1 and neoplasm: This PANC‐1 model was selected because it is a well‐established PC model with the oncogenic KRASG12D mutation.[29, 30] In comparison, as a control, GEM was weekly i.v. administered at a dose of 5 mg kg−1 due to its short circulation half‐life (0.28 h).[31] After two ADC injections, the ICAM1‐DM1‐treated group exhibited a potent and durable tumor regression compared to other groups (Figure 3G–H).